Project Grant S10OD036228
Award Date
7/15/24
Completion Date
6/30/25
Dollars Obligated
$1M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
Aggregate Financial Assistance Data
Federal Grant Program
93.351
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This $639,794 federal grant award from the National Science Foundation's (NSF) Integrative Activities program (CFDA 47.083) supports the acquisition of an Illumina NextSeq 2000 next-generation DNA sequencing instrument for the Design, Automation, Manufacturing, and Process (DAMP) Laboratory at Boston University. The new sequencing instrument will enable DAMP Lab researchers to study the genomic sequences of novel molecular tools they are developing, which can lead to improvements in drug design,...
This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $1,078,438 to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to upgrade the institution's high-throughput genomic sequencing capabilities. Specifically, the award will fund the acquisition of an Illumina NovaSeq X Plus Sequencing System, which will enhance the research capabilities of the institution's Genomics Core. This upgrade is...
This $749,999 Project Grant was awarded on June 15, 2024 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The grant will fund the University of Arkansas for Medical Sciences (UAMS) to replace their existing Illumina NovaSeq 6000 next-generation sequencing (NGS) system with the new Illumina NovaSeq X Plus NGS system. This upgrade will: Reduce sequencing costs by up to 80% compared to the current system,...
This $955,000 federal Project Grant award, funded by the National Institute of Standards and Technology (NIST) under the Congressionally-Identified Projects program (CFDA 11.617), will enable HMH Hospitals Corporation to establish a nanopore long-read DNA sequencing capability as a core facility for the HMH hospital system. Key activities include procuring high-throughput sequencing instruments, high-performance computing resources, and bioinformatics pipelines. This core facility will support...
The National Cancer Institute (NCI) awarded a $872,555 Cooperative Agreement (Federal Grant Award ID: U24CA294203) under the Cancer Biology Research (CFDA 93.396) federal grant program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The objective of this 5-year project is to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key activities...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,507,500 in funding to the University of Massachusetts Medical School (UMass Medical) to expand the capabilities of third-generation sequencing technologies like nanopore sequencing. The primary objectives are to: 1) Generate training libraries to allow for direct detection of common damaged DNA bases resulting from oxidation or...
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) aims to develop a revolutionary DNA sequencing platform that surpasses existing technologies in accuracy and cost. The $384,418 award to Xgenomes Corp. will fund the development of a super-resolution single-molecule sequencing method that can read short sequence "words" rather than single nucleotides, enabling highly accurate and cost-effective genomic analysis. The...
This Project Grant award, valued at $215,088, was provided by the National Human Genome Research Institute (NHGRI) under the Human Genome Research Federal Grant Program (CFDA 93.172). The grant supports the development of an "exhaustive de novo RNA sequencing method" by Directseq Biosciences, Inc., a small disadvantaged business based in Schenectady, New York. This innovative technology, referred to as Next-Generation Mass Spectrometry-based Sequencing (NGMS-SEQ), aims to...
This $406,500 federal Project Grant from the National Human Genome Research Institute (NHGRI), under the Human Genome Research program (CFDA 93.172), aims to advance "Next-Generation Mass Spectrometry-based Sequencing (NGMS-SEQ)" methods for high-throughput, bias-free sequencing and quantitative mapping of RNA modifications. The funded research seeks to: 1) enhance NGMS-SEQ techniques to directly sequence tRNA samples, including physiologically relevant ones, and 2) improve...
The National Cancer Institute (NCI) awarded a $942,442 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) to identify the mechanisms driving rapid evolution of cancer genomes. The research aims to understand the processes of "chromothripsis," a catastrophic mutational event that involves massive chromosome rearrangement, as well as "chromoplexy," another poorly understood mutational process...